{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=QTc+Interval&page=2",
    "query": {
      "condition": "QTc Interval",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=QTc+Interval&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T22:43:29.887Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04312282",
      "title": "The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Tesetaxel",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Odonate Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2020-03-06",
      "completion_date": "2021-06-15",
      "has_results": false,
      "last_update_posted_date": "2021-07-28",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 3,
      "location_summary": "Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04312282"
    },
    {
      "nct_id": "NCT03958123",
      "title": "Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prolonged QTc Interval",
        "Pharmacokinetic"
      ],
      "interventions": [
        {
          "name": "100 μg cebranopadol",
          "type": "DRUG"
        },
        {
          "name": "200 μg cebranopadol",
          "type": "DRUG"
        },
        {
          "name": "400 μg cebranopadol",
          "type": "DRUG"
        },
        {
          "name": "Placebo to cebranopadol encapsulated tablets",
          "type": "DRUG"
        },
        {
          "name": "400 mg Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to moxifloxacin encapsulated tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 171,
      "start_date": "2013-07-10",
      "completion_date": "2013-11-27",
      "has_results": false,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03958123"
    },
    {
      "nct_id": "NCT00789568",
      "title": "A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Phenylketonuria"
      ],
      "interventions": [
        {
          "name": "sapropterin dihydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2008-10",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00789568"
    },
    {
      "nct_id": "NCT02307864",
      "title": "Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tramadol HCl",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Tramadol HCl Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 68,
      "start_date": "2014-12-04",
      "completion_date": "2015-08-27",
      "has_results": false,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02307864"
    },
    {
      "nct_id": "NCT03418077",
      "title": "Post-Exercise Cardiovascular Responses Following Energy Drink Consumption",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "QTc Interval"
      ],
      "interventions": [
        {
          "name": "Energy Drink",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo-control",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "David Grant U.S. Air Force Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 28,
      "start_date": "2018-05-07",
      "completion_date": "2019-05-31",
      "has_results": false,
      "last_update_posted_date": "2020-04-17",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 1,
      "location_summary": "Travis Air Force Base, California",
      "locations": [
        {
          "city": "Travis Air Force Base",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03418077"
    },
    {
      "nct_id": "NCT06746402",
      "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BMS-986278",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2025-02-10",
      "completion_date": "2025-09-11",
      "has_results": false,
      "last_update_posted_date": "2025-10-06",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06746402"
    },
    {
      "nct_id": "NCT02027454",
      "title": "Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1265744",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2014-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02027454"
    },
    {
      "nct_id": "NCT05924815",
      "title": "Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Aficamten",
          "type": "DRUG"
        },
        {
          "name": "Aficamten-matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cytokinetics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 44,
      "start_date": "2023-05-15",
      "completion_date": "2023-11-14",
      "has_results": false,
      "last_update_posted_date": "2023-12-19",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05924815"
    },
    {
      "nct_id": "NCT01812538",
      "title": "A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ventricular Repolarization"
      ],
      "interventions": [
        {
          "name": "DIC075V",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospira, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 70,
      "start_date": "2009-05",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2015-07-24",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01812538"
    },
    {
      "nct_id": "NCT05391022",
      "title": "Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancies",
        "Solid Tumor",
        "Hematological Malignancy"
      ],
      "interventions": [
        {
          "name": "Pelabresib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Constellation Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2021-07-20",
      "completion_date": "2024-02-29",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-06-25T22:43:29.887Z",
      "location_count": 3,
      "location_summary": "Canton, Ohio • Gettysburg, Pennsylvania • West Valley City, Utah",
      "locations": [
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Gettysburg",
          "state": "Pennsylvania"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05391022"
    }
  ]
}